Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress.

Cancer letters·2025

Same author

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress.

Redox biology·2023

Same author

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.

Journal for immunotherapy of cancer·2023

Same author

A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation.

Carcinogenesis·2021

Same author

Metabolic reprogramming in renal cancer: Events of a metabolic disease.

Biochimica et biophysica acta. Reviews on cancer·2021

Same author

Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations.

Cytokine·2020

Search research articles

Related Experiment Video

Updated: May 26, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Interferon lambda: a new sword in cancer immunotherapy.

Ahmed Lasfar¹, Walid Abushahba, Murugabaskar Balan

¹Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, University Hospital Cancer Center, Newark, NJ 07103, USA. lasfarah@gmail.com

Clinical & Developmental Immunology

|December 23, 2011

Summary

This summary is machine-generated.

Interferon-lambda (IFN-λ), a type III interferon, shows potent antitumor effects. Its targeted response in epithelial cells suggests a promising new avenue for cancer therapy with potentially fewer side effects.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Experiment Videos

Last Updated: May 26, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Area of Science:

Immunology
Oncology
Virology

Background:

The discovery of interferon-lambda (IFN-λ) has expanded the understanding of interferon roles beyond viral infections into cancer.
IFN-λ, a type III interferon, shares structural similarities with type II IFN (IFN-γ) and functional similarities with type I IFN (IFN-α/β).

Purpose of the Study:

To explore the role of IFN-λ in cancer, building upon its known functions in viral infections.
To highlight the unique cell-type specific response pattern of IFN-λ and its implications for therapeutic development.

Main Methods:

Comparative analysis of IFN-λ's structural and functional properties against other interferon types.
Investigation of IFN-λ's cell-type specific response, focusing on epithelial-like and immune cells.
Review of recent animal model studies demonstrating the antitumor activity of IFN-λ.

Main Results:

IFN-λ exhibits a highly cell-type specific response, primarily engaging epithelial-like cells and some immune cells.
The differential expression of the IFN-λ receptor dictates this specific response pattern.
Recent studies in animal models have confirmed a potent antitumor role for IFN-λ.

Conclusions:

IFN-λ represents a novel class of interferons with significant potential in cancer treatment.
The targeted cellular response of IFN-λ may lead to reduced side effects compared to other interferon therapies.
IFN-λ therapy opens a new frontier in the management of cancer, complementing existing interferon treatments.